

10/527708

DT09 Rec'd PCT/PTO 11 MAR 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	Based on PCT/JP2003/011631	Art Unit:	tba
Filed:	Intl. Filing 11 SEPTEMBER 2003	Examiner:	tba
1 st Inventor:	Hideki MATSUI	Allowed:	
For:	Preventives/Remedies For Neurodegenerative Disease	Batch:	
Atty. Dkt. No.	3097 USOP	Paper No.:	

Information Disclosure Statement

MAIL STOP PCT
P.O. Box 1450
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Form PTO/SB/08A and 08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.


Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated: 3/11/05

(847) 383-3372
(847) 383-3391

Respectfully submitted,



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	Based on PCT/JP2003/011631
Filing Date	Intl. Filing 11 SEPTEMBER 2003
First Named Inventor	H. MATSUI
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3097 USOP

[illegible]

FOREIGN PATENT DOCUMENTS						T ⁶
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
	A1	WO 01/38503 A2	05/31/2001	Sugen, Inc.		

**Examiner
Signature**

Date Considered	
-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

10/527708

Application Number		Based on PCT/JP2003/011631	
Filing Date		Intl. Filing 11 SEPTEMBER 2003	
First Named Inventor		H. MATSUI	
Art Unit		tba	
Examiner Name		tba	
Attorney Docket Number		3097 US0P	
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A2	KEIKO MAYUMI-MATSUDA, et al., "Identification of a Novel Kinase-like Gene Induced During Neuronal Cell Death", Biochemical and Biophysical Research Communications, (1999), pp. 260-264, Vol. 258.	
	A3	YUZURU IMAI, et al., "An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin", Cell, (2001), pp. 891-902, Vol. 105.	
	A4	KASUNORI IMAIZUMI, et al., "The Unfolded Protein Response and Alzheimer's Disease". Biochimica et Biophysica Acta, (2001), pp. 85-96, Vol. 1536	
	A5	NAOYA SATO, et al., "Increased Production of Beta-Amyloid and Vulnerability to Endoplasmic Reticulum Stress by an Aberrant Spliced Form of Presenilin 2", The Journal of Biological Chemistry, (2001), pp. 2108-2114, Vol. 276, No. 3	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.